tofacitinib
FDA Approves Tofacitinib for Active Ankylosing Spondylitis
The FDA has approved a supplemental New Drug Application for tofacitinib for the treatment of adults with ...
DECEMBER 17, 2021
FDA Warns of Serious Risks, Including Death, With JAK Inhibitors
The FDA is requiring the addition of warnings about increased risks for cancer, serious cardiovascular events and ...
SEPTEMBER 28, 2021
JAK Inhibitors, IL-6 Blockers for COVID-19: Where Do They Fit?
Another JAK inhibitor appears effective in reducing death and respiratory failure in patients hospitalized with ...
JULY 7, 2021
Tofacitinib Data Shed Light on DVT/PE Rates
Clinicians and patients with ulcerative colitis, rheumatoid arthritis, psoriatic arthritis or ankylosing ...
SEPTEMBER 30, 2020
Load more